Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.

Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH.

Gynecol Oncol. 2019 Feb;152(2):328-333. doi: 10.1016/j.ygyno.2018.12.001. Epub 2018 Dec 8.

2.

ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression.

Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC.

Cancers (Basel). 2018 Nov 22;10(12). pii: E464. doi: 10.3390/cancers10120464.

3.

MODELING DEPENDENT GENE EXPRESSION.

Telesca D, Müller P, Parmigiani G, Freedman RS.

Ann Stat. 2012;6(2):542-560. doi: 10.1214/11-AOAS525. Epub 2012 Jun 11.

4.

2013 HIPAA Changes Provide Opportunities and Challenges for Researchers: Perspectives from a Cancer Center.

Freedman RS, Cantor SB, Merriman KW, Edgerton ME.

Clin Cancer Res. 2016 Feb 1;22(3):533-9. doi: 10.1158/1078-0432.CCR-15-2155.

5.

Is conflict of interest becoming a challenge for institution-based institutional review boards?

Freedman RS, McKinney R Jr.

Clin Cancer Res. 2013 Aug 1;19(15):4034-9. doi: 10.1158/1078-0432.CCR-13-0543. Epub 2013 Jun 5.

6.

CHEMICAL CONSEQUENCES OF THE C/O RATIO ON HOT JUPITERS: EXAMPLES FROM WASP-12b, COROT-2b, XO-1b, AND HD 189733b.

Moses JI, Madhusudhan N, Visscher C, Freedman RS.

Astrophys J. 2012;763(1). pii: 25. doi: 10.1088/0004-637X/763/1/25. Epub 2012 Dec 20.

7.

Staging early ovarian cancer: impact on treatment decisions.

Freedman RS.

Eur J Cancer. 2010 Mar;46(5):856-8. doi: 10.1016/j.ejca.2010.01.017. Epub 2010 Feb 16. No abstract available.

PMID:
20163951
8.

Differential expression of CD3zeta message and protein in tumor infiltrating lymphocytes from solid tumor specimens and malignant ascites from patients with ovarian carcinoma.

Pappas J, Wolfson AD, Jung WJ, Oleszak EL, Helm CW, Freedman RS, Tsygankov AY, Platsoucas CD.

Anticancer Res. 2009 Nov;29(11):4673-82.

9.

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.

Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS.

Gynecol Oncol. 2009 May;113(2):210-5. doi: 10.1016/j.ygyno.2009.02.007. Epub 2009 Mar 4.

10.

14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients.

Kobayashi R, Deavers M, Patenia R, Rice-Stitt T, Halbe J, Gallardo S, Freedman RS.

Cancer Immunol Immunother. 2009 Feb;58(2):247-58. doi: 10.1007/s00262-008-0549-7. Epub 2008 Jul 11.

PMID:
18618111
11.

Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis.

Cole ME, Broaddus R, Thaker P, Landen C, Freedman RS.

Nat Clin Pract Oncol. 2008 Mar;5(3):171-5. doi: 10.1038/ncponc1042. Review.

PMID:
18227827
13.

Migration deficit in monocyte-macrophages in human ovarian cancer.

Freedman RS, Ma Q, Wang E, Gallardo ST, Gordon IO, Shin JW, Jin P, Stroncek D, Marincola FM.

Cancer Immunol Immunother. 2008 May;57(5):635-45. Epub 2007 Oct 10.

PMID:
17926037
14.

Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.

Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL Jr, Deavers M, Marincola FM, Yang P, Newman RA.

Clin Cancer Res. 2007 Oct 1;13(19):5736-44.

15.

Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.

Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J.

Neoplasia. 2007 Jun;9(6):479-86.

16.

Food and drug administration expanded access to treatment: implications for oncology patients.

Freedman RS, Markman M.

Cancer. 2007 Jun 1;109(11):2157-60. No abstract available.

17.

Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.

Melichar B, Patenia R, Gallardo S, Melicharová K, Hu W, Freedman RS.

Gynecol Oncol. 2007 Mar;104(3):707-13. Epub 2006 Dec 12.

PMID:
17166566
18.

Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees.

SCT Working Group on Data Monitoring, Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM.

Clin Trials. 2006;3(3):314-9.

PMID:
16895048
19.

Immunobiology of gestational trophoblastic diseases.

Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ.

Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1500-15. Review.

PMID:
16884358
20.

Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease.

Wang X, Deavers M, Patenia R, Bassett RL Jr, Mueller P, Ma Q, Wang E, Freedman RS.

J Transl Med. 2006 Jul 6;4:30.

21.

Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Apte SM, Vadhan-Raj S, Cohen L, Bassett RL, Gordon IO, Levenback CF, Ramirez PT, Gallardo ST, Patenia RS, Garcia ME, Iyer RB, Freedman RS.

J Transl Med. 2006 Apr 7;4:16.

22.

Common cancer biomarkers.

Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR, Hu N, Zanovello P, Marincola FM, Wang E.

Cancer Res. 2006 Mar 15;66(6):2953-61.

23.
24.

Venous thromboembolism syndrome in gynecological cancer.

Wang X, Fu S, Freedman RS, Kavanagh JJ.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:458-71. Review.

PMID:
16515646
25.

Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies.

Melichar B, Solichová D, Freedman RS.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):240-52. Review.

PMID:
16445639
26.

Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumors.

Pappas J, Jung WJ, Barda AK, Lin WL, Fincke JE, Purev E, Radu M, Gaughan J, Helm CW, Hernandez E, Freedman RS, Platsoucas CD.

Cell Immunol. 2005 Apr;234(2):81-101.

PMID:
16038891
27.

Ovarian cancer, the coagulation pathway, and inflammation.

Wang X, Wang E, Kavanagh JJ, Freedman RS.

J Transl Med. 2005 Jun 21;3:25.

28.

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.

Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S.

Oncol Res. 2005;15(1):49-57.

PMID:
15839305
29.

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.

See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):209-16.

30.

Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer.

Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola FM.

Clin Cancer Res. 2005 Jan 1;11(1):113-22.

31.

Melanoma-restricted genes.

Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM.

J Transl Med. 2004 Oct 15;2(1):34.

32.

Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).

Freedman RS, Deavers M, Liu J, Wang E.

J Transl Med. 2004 Jun 25;2(1):23.

33.

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.

Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM.

Bone Marrow Transplant. 2004 Jun;33(12):1219-24.

PMID:
15122311
34.

Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.

Borchardt PE, Vriesendorp HM, Freedman RS, Quadri SM.

Cancer Biother Radiopharm. 2004 Feb;19(1):43-51.

PMID:
15068610
36.

Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.

Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ.

Proteomics. 2003 Oct;3(10):1904-11.

PMID:
14625852
37.

Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.

Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME.

Clin Cancer Res. 2003 Nov 1;9(14):5228-37.

38.

Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma.

Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS.

Int J Gynecol Cancer. 2003 Jul-Aug;13(4):435-43.

PMID:
12911719
39.

Immune responses to human tumors: development of tumor vaccines.

Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS.

Anticancer Res. 2003 May-Jun;23(3A):1969-96. Review.

PMID:
12894571
40.

Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.

Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS.

J Immunother. 2003 May-Jun;26(3):270-6.

PMID:
12806280
41.

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC.

Clin Cancer Res. 2003 Feb;9(2):845-52.

42.

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS.

Clin Cancer Res. 2002 Dec;8(12):3686-95.

43.

Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study.

Gordinier ME, Kudelka AP, Kavanagh JJ, Wharton JT, Freedman RS.

Int J Gynecol Cancer. 2002 Nov-Dec;12(6):710-4.

PMID:
12445247
44.

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.

Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B.

Lancet. 2002 Jun 22;359(9324):2145-52.

PMID:
12090979
45.

The expression of decorin in human ovarian tumors.

Nash MA, Deavers MT, Freedman RS.

Clin Cancer Res. 2002 Jun;8(6):1754-60.

46.

Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.

Hu W, Wu W, Yeung SC, Freedman RS, Kavanagh JJ, Verschraegen CF.

Anticancer Res. 2002 Mar-Apr;22(2A):665-72.

PMID:
12014635
47.

The immunotherapy of patients with ovarian cancer.

Hwu P, Freedman RS.

J Immunother. 2002 May-Jun;25(3):189-201. Review.

PMID:
12000860
48.

Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.

Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ.

Int J Gynecol Cancer. 2002 Mar-Apr;12(2):202-7.

PMID:
11975681
49.

Immunology of the peritoneal cavity: relevance for host-tumor relation.

Melichar B, Freedman RS.

Int J Gynecol Cancer. 2002 Jan-Feb;12(1):3-17. Review.

PMID:
11860531
50.

Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.

Azevedo P, Verschraegen CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT.

Eur J Gynaecol Oncol. 2001;22(5):319-21. No abstract available.

PMID:
11766729

Supplemental Content

Loading ...
Support Center